Overview

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Eligibility

Inclusion Criteria:

• Male or eligible female participants
• Participants with \>=40 to less than or equal to (\<=) 80 years of age.
• An eosinophilic phenotype with elevated BEC.
• Moderate to very severe COPD with frequent exacerbations.
• Participants with elevated COPD assessment test (CAT) score.
• Current or former cigarette smokers.
• On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.

Exclusion Criteria:

• Current or prior physician diagnosis of asthma
• Other clinically significant lung disease.
• Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
• Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.
• Continuous oxygen therapy (more than 16 hours/ day).
• Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.
• A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).
• Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.
• New York Heart Association class III or IV heart failure.
• Other significant medical conditions that could impact participants' safety or study outcomes.